Finding new ways to treat chemotherapy-resistant ovarian cancer.
BCCMA: Overcoming chemoresistance in ovarian cancer: Targeting Unique Vulnerabilities in Neuroendocrine-like Ovarian Cancer Cells
This study is looking at ways to help women with high-grade serous ovarian cancer who aren't responding to standard chemotherapy, by finding new targets and markers that could lead to better treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Greater Los Angeles Healthcare System NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10903725 on NIH RePORTER |
What this research studies
This research focuses on understanding and overcoming the challenges of chemotherapy resistance in high-grade serous ovarian carcinoma (HGSOC), the most common and deadly form of ovarian cancer. The project aims to identify novel targets and biomarkers that can help in treating patients whose tumors have become resistant to standard platinum-based chemotherapy. By studying the mechanisms that lead to this resistance, researchers hope to develop new therapeutic strategies that can improve patient outcomes. The approach involves interdisciplinary collaboration and advanced techniques to gain insights into the cancer cells' behavior and their environment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-grade serous ovarian carcinoma who have experienced relapse after chemotherapy.
Not a fit: Patients with other types of ovarian cancer or those who have not undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with chemotherapy-resistant ovarian cancer, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in targeting unique vulnerabilities in cancer cells, suggesting that this approach could be effective.
Where this research is happening
Los Angeles, United States
- VA Greater Los Angeles Healthcare System — Los Angeles, United States (Active)
Researchers
- Principal investigator: Memarzadeh, Sanaz — VA Greater Los Angeles Healthcare System
- Study coordinator: Memarzadeh, Sanaz
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.